Cantor Fitzgerald Comments on Immatics FY2026 Earnings

Immatics (NASDAQ:IMTX - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for shares of Immatics in a research report issued on Monday, June 9th. Cantor Fitzgerald analyst E. Schmidt anticipates that the company will post earnings of ($1.50) per share for the year. Cantor Fitzgerald has a "Overweight" rating on the stock. The consensus estimate for Immatics' current full-year earnings is ($0.72) per share.

Other equities analysts have also recently issued research reports about the stock. Wall Street Zen cut shares of Immatics from a "hold" rating to a "strong sell" rating in a research report on Thursday, May 22nd. Deutsche Bank Aktiengesellschaft initiated coverage on Immatics in a report on Wednesday, May 28th. They set a "buy" rating and a $10.00 price target on the stock. One research analyst has rated the stock with a sell rating, four have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $14.67.

Immatics Price Performance

IMTX traded down $0.02 during trading on Tuesday, hitting $6.12. 536,153 shares of the stock traded hands, compared to its average volume of 654,727. The firm has a market capitalization of $743.89 million, a P/E ratio of -9.27 and a beta of 0.83. The firm has a 50-day moving average of $4.91 and a 200 day moving average of $5.46. Immatics has a 12-month low of $3.30 and a 12-month high of $13.37.

Immatics (NASDAQ:IMTX - Get Free Report) last issued its earnings results on Tuesday, May 13th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.04. Immatics had a negative net margin of 47.94% and a negative return on equity of 15.90%. The firm had revenue of $20.12 million for the quarter, compared to analysts' expectations of $14.92 million.

Institutional Investors Weigh In On Immatics

Several institutional investors and hedge funds have recently modified their holdings of IMTX. Bank of America Corp DE raised its stake in Immatics by 166.0% in the fourth quarter. Bank of America Corp DE now owns 3,575 shares of the company's stock worth $25,000 after buying an additional 2,231 shares in the last quarter. Virtus ETF Advisers LLC boosted its position in Immatics by 34.8% during the 4th quarter. Virtus ETF Advisers LLC now owns 9,594 shares of the company's stock valued at $68,000 after acquiring an additional 2,479 shares in the last quarter. Intellectus Partners LLC purchased a new position in shares of Immatics during the 1st quarter worth approximately $70,000. Guggenheim Capital LLC bought a new position in shares of Immatics in the 4th quarter worth approximately $101,000. Finally, Forefront Analytics LLC raised its position in shares of Immatics by 42.3% in the 4th quarter. Forefront Analytics LLC now owns 15,911 shares of the company's stock worth $113,000 after acquiring an additional 4,731 shares in the last quarter. 64.41% of the stock is owned by hedge funds and other institutional investors.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.